Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 1
1995 1
1996 5
1997 4
1998 11
1999 6
2000 13
2001 7
2002 6
2003 5
2004 6
2005 6
2006 7
2007 4
2008 4
2009 1
2010 5
2011 3
2012 4
2013 8
2014 7
2015 7
2016 11
2017 6
2018 14
2019 14
2020 15
2021 26
2022 19
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. Izutsu K, et al. Among authors: yonekura k. Blood. 2023 Mar 9;141(10):1159-1168. doi: 10.1182/blood.2022016862. Blood. 2023. PMID: 36150143 Free PMC article. Clinical Trial.
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H. Sootome H, et al. Among authors: yonekura k. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24. Cancer Res. 2020. PMID: 32973082
Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Yanase T, Tsuruta N, Yamaguchi K, Ohata C, Ohyama B, Katayama E, Sugita K, Kuwashiro M, Hashimoto A, Yonekura K, Higashi Y, Murota H, Koike Y, Matsuzaka Y, Kikuchi S, Hatano Y, Saito K, Takahashi K, Miyagi T, Kaneko S, Ota M, Harada K, Morizane S, Ikeda K, Furue M, Nakahara T, Okazaki F, Sasaki N, Okada E, Yoshida Y, Ito K, Imafuku S. Yanase T, et al. Among authors: yonekura k. J Dermatol. 2023 Jun;50(6):753-765. doi: 10.1111/1346-8138.16737. Epub 2023 Feb 14. J Dermatol. 2023. PMID: 36786158
Nonsupersymmetric Heterotic Branes.
Kaidi J, Ohmori K, Tachikawa Y, Yonekura K. Kaidi J, et al. Among authors: yonekura k. Phys Rev Lett. 2023 Sep 22;131(12):121601. doi: 10.1103/PhysRevLett.131.121601. Phys Rev Lett. 2023. PMID: 37802929
[A Case of Extrarenal Retroperitoneal Angiomyolipoma].
Saito T, Watanabe Y, Ishii T, Yonekura K, Sanada T, Kuwabara H, Nakamura N, Goseki N. Saito T, et al. Among authors: yonekura k. Gan To Kagaku Ryoho. 2017 Nov;44(12):1346-1348. Gan To Kagaku Ryoho. 2017. PMID: 29394629 Review. Japanese.
Total Synthesis of the Sesquiterpene (-)-Merrillianin.
Shiina I, Iizumi T, Taniguchi S, Sugimoto M, Shimazaki T, Yamai YS, Ogawa G, Yamada T, Shinohara S, Kageyama Y, Kuboki T, Suwa Y, Yonekura K, Ito K, Toyoyama K, Tateyama S, Mori T, Murata T. Shiina I, et al. Among authors: yonekura k. Org Lett. 2024 Apr 26;26(16):3327-3331. doi: 10.1021/acs.orglett.3c03877. Epub 2023 Dec 31. Org Lett. 2024. PMID: 38160411
233 results